The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | AL amyloidosis special session highlights: therapeutic advances and ongoing trials in the field
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, gives an overview of therapeutic advances made in the field of light chain (AL) amyloidosis, commenting on novel anti-fibril agents being explored. Prof. Sanchorawala shares insights into ongoing trials exploring these novel agents, including the AFFIRM-AL trial and the CAEL101-302 trial (NCT04973137; NCT04512235). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
